ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have been given a consensus rating of "Buy" by the eight research firms that are covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $8.00.

A number of equities research analysts have recently commented on PRQR shares. Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target on the stock in a report on Monday, March 10th. HC Wainwright increased their price target on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, March 14th. Cantor Fitzgerald started coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They set an "overweight" rating and a $8.00 price target on the stock. Evercore ISI initiated coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They set an "outperform" rating and a $5.00 price target on the stock. Finally, Chardan Capital restated a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in shares of ProQR Therapeutics during the 4th quarter worth $30,000. Invesco Ltd. bought a new stake in ProQR Therapeutics in the 4th quarter valued at $32,000. Alpine Global Management LLC bought a new stake in ProQR Therapeutics in the 4th quarter valued at $39,000. Two Sigma Securities LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth about $40,000. Finally, Vontobel Holding Ltd. bought a new stake in shares of ProQR Therapeutics in the 1st quarter worth about $48,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Trading Down 0.3%

PRQR traded down $0.01 during midday trading on Friday, reaching $1.55. The company's stock had a trading volume of 65,881 shares, compared to its average volume of 620,222. The firm has a market capitalization of $162.55 million, a price-to-earnings ratio of -4.83 and a beta of 0.35. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The stock's 50-day moving average is $1.47 and its 200-day moving average is $2.37.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The business had revenue of $4.89 million during the quarter, compared to analysts' expectations of $4.90 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. As a group, equities research analysts forecast that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).